Literature DB >> 12918127

p53 protein expression and CA19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis.

De-Qing Mu1, Guo-Feng Wang, Shu-You Peng.   

Abstract

AIM: To evaluate p53 protein overexpression and to measure serum CA19.9 concentrations in cytological diagnosis of patients with suspected pancreatic cancer.
METHODS: 24 patients with suspected pancreatic cancer due to chronic pancreatitis, had a pancreatic mass determined by imaging methods. The serum CA19.9 concentration was measured by solid phase radioimmunoassay. On laparotomy, puncture biopsy was performed, and specimens were divided into two parts for cytological diagnosis and detection of p53 protein.
RESULTS: Cytology offered a sensitivity of 0.63, a specificity of 1.00, and an accuracy of 0.63. p53 protein analysis offered a sensitivity of 0.44, a specificity of 1.00, and an accuracy of 0.73. CA19.9 offered a sensitivity of 0.44, a specificity of 0.80, and an accuracy of 0.67. The combined cytology and p53 protein analysis showed a sensitivity of 0.78, a specificity of 1.00, and an accuracy of 0.92. Cytology and CA19.9 showed a sensitivity of 0.67, a specificity of 0.80, an accuracy of 0.67. combined cytology and p53 protein analysis and CA19.9 showed a sensitivity of 0.78, a specificity of 0.80,and an accuracy of 0.79.
CONCLUSION: Superior to any single test, the combined approach is helpful for the differential diagnosis of pancreatic cancer complicated with chronic pancreatitis. The combined cytology and p53 protein analysis offers the best diagnostic efficacy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12918127      PMCID: PMC4611550          DOI: 10.3748/wjg.v9.i8.1815

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

Review 1.  Pancreatic carcinoma.

Authors:  S Rosewicz; B Wiedenmann
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

2.  Pancreatic carcinoma associated with chronic pancreatitis.

Authors:  H Wakasugi; A Funakoshi; H Iguchi; M Takase; M Inoue; A Ohshima; Y Seo
Journal:  Intern Med       Date:  1999-12       Impact factor: 1.271

Review 3.  Tissue sampling at ERCP in suspected pancreatic cancer.

Authors:  J G Lee; J Leung
Journal:  Gastrointest Endosc Clin N Am       Date:  1998-01

4.  A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.

Authors:  H J Kim; M H Kim; S J Myung; B C Lim; E T Park; K S Yoo; D W Seo; S K Lee; Y I Min
Journal:  Am J Gastroenterol       Date:  1999-07       Impact factor: 10.864

5.  Expression of various sialylated carbohydrate antigens in malignant and nonmalignant pancreatic tissues.

Authors:  Y Satomura; N Sawabu; Y Takemori; H Ohta; H Watanabe; T Okai; K Watanabe; H Matsuno; F Konishi
Journal:  Pancreas       Date:  1991-07       Impact factor: 3.327

6.  Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases.

Authors:  K Yamaguchi; K Chijiiwa; H Noshiro; N Torata; M Kinoshita; M Tanaka
Journal:  Hepatogastroenterology       Date:  1999 Jul-Aug

7.  Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma.

Authors:  M Tada; M Omata; S Kawai; H Saisho; M Ohto; R K Saiki; J J Sninsky
Journal:  Cancer Res       Date:  1993-06-01       Impact factor: 12.701

8.  Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group.

Authors:  A B Lowenfels; P Maisonneuve; G Cavallini; R W Ammann; P G Lankisch; J R Andersen; E P Dimagno; A Andrén-Sandberg; L Domellöf
Journal:  N Engl J Med       Date:  1993-05-20       Impact factor: 91.245

9.  Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon.

Authors:  J C Luo; A I Neugut; G Garbowski; K A Forde; M Treat; S Smith; W P Carney; P W Brandt-Rauf
Journal:  Cancer Lett       Date:  1995-05-08       Impact factor: 8.679

10.  CA 19-9 and pancreatic adenocarcinoma.

Authors:  F Safi; H G Beger; R Bittner; M Büchler; W Krautzberger
Journal:  Cancer       Date:  1986-02-15       Impact factor: 6.860

View more
  5 in total

1.  Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.

Authors:  Jing-Ting Jiang; Chang-Ping Wu; Hai-Feng Deng; Ming-Yang Lu; Jun Wu; Hong-Yu Zhang; Wen-Hui Sun; Mei Ji
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

Review 2.  Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.

Authors:  Si-Biao Su; Shan-Yu Qin; Wen Chen; Wei Luo; Hai-Xing Jiang
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

3.  Lateral flow assay for carbohydrate antigen 19-9 in whole blood by using magnetized carbon nanotubes.

Authors:  Yan Huang; Yongqiang Wen; Kwaku Baryeh; Sunitha Takalkar; Michelle Lund; Xueji Zhang; Guodong Liu
Journal:  Mikrochim Acta       Date:  2017-08-25       Impact factor: 5.833

Review 4.  Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.

Authors:  Chakshu Sharma; Karim M Eltawil; Paul D Renfrew; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

Review 5.  A quarter century of EUS-FNA: Progress, milestones, and future directions.

Authors:  Irina Mihaela Cazacu; Adriana Alexandra Luzuriaga Chavez; Adrian Saftoiu; Peter Vilmann; Manoop S Bhutani
Journal:  Endosc Ultrasound       Date:  2018 May-Jun       Impact factor: 5.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.